FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
F. Hoffmann-La Roche Ltd Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly…
Can Novartis’ Fabhalta Strengthen Its Nephrology Franchise?
Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline…
Novartis (SWX:NOVN) Wins Full FDA Nod For Fabhalta And Wider EU Itvisma Use
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Novartis…
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow…
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartis Pharma AG Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 …
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartis Pharma AG Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 …
Novartis reports positive results from Phase III ALIGN trial for IgAN
Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slows kidney function…
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Novartis Pharma AG Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with…
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Novartis Pharma AG Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with…
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Novartis Pharma AG Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with…
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…